×
Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19

Nov 23rd, 2020 - For Immediate Release: November 19, 2020 Español Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, o...

Actualización sobre el coronavirus (COVID-19): La FDA autoriza una combinación de medicamentos para el tratamiento del COVID-19 | FDA
https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-una-combinacion-de-medicamentos-para-el

Nov 23rd, 2020 - For Immediate Release: November 19, 2020 English Hoy, la Administración de Alimentos y Medicamentos de los EE.UU. (FDA, por sus siglas en inglés) emitió una autorización de uso de emergencia (EUA) para el medicamento baricitinib, en combinación con remdesivir, para el tratamiento de COVID-19 sospechado o confirmado por un laboratorio en adultos hospitalizados y pacientes pediátricos de dos años...

An effective drug against COVID-19: reality or dream?
https://doi.org/10.1080/17476348.2021.1854092
Expert Review of Respiratory Medicine; Yaghoubi A, Amel Jamehdar S et. al.

Nov 20th, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well known as a novel member of the coronavirus family which caused a sudden outbreak of Coronavirus disease 2019 (COVID-19) in Wuhan, China that quickly developed into a global pandemic. No effective approaches are found as yet for the therapy and epidemiological control of this new virus. For this purpose, we searched the literat...

A bacterial artificial chromosome (BAC)-vectored noninfectious replicon of SARS-CoV-2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670965
Antiviral Research; Zhang Y, Song W et. al.

Nov 20th, 2020 - Vaccines and antiviral agents are in urgent need to stop the COVID-19 pandemic. To facilitate antiviral screening against SARS-CoV-2 without requirement for high biosafety level facility, we developed a bacterial artificial chromosome (BAC)-vectored replicon of SARS-CoV-2, nCoV-SH01 strain, in which secreted Gaussia luciferase (sGluc) was encoded in viral subgenomic mRNA as a reporter gene. The...

Covid-19: What now for remdesivir?
https://doi.org/10.1136/bmj.m4457
BMJ (Clinical Research Ed.); Hsu J

Nov 20th, 2020 - Covid-19: What now for remdesivir?|2020|Hsu J,|

Coronavirus (COVID-19) Update: November 20, 2020 | FDA
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-november-20-2020

Nov 20th, 2020 - For Immediate Release: November 20, 2020 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The FDA, yesterday, issued an EUA for the drug baricitinib (Olumiant), in combination with remdesivir (Veklury) for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric pati...

Remdesivir: A beacon of hope from Ebola virus disease to COVID-19.
https://doi.org/10.1002/rmv.2133
Reviews in Medical Virology REFERENCES; Nili A, Farbod A et. al.

Nov 19th, 2020 - Since the emergence of coronavirus disease 2019 (Covid-19), many studies have been performed to characterize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and find the optimum way to combat this virus. After suggestions and assessments of several therapeutic options, remdesivir (GS-5734), a direct-acting antiviral drug previously tested against Ebola virus disease, was found to b...

FDA Authorizes Baricitinib Combo for COVID-19
https://www.staging.medscape.com/viewarticle/941324

Nov 18th, 2020 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. The US Food and Drug Administration (FDA) today issued an emergency use authorization (EUA) for the janus kinase inhibitor baricitinib (Olumiant, Eli Lilly) in combination with remdesivir (Veklury, Gilead) for treating hospitalized adults and children at least 2 years old with suspected or confi...

Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized wi...
https://doi.org/10.1161/CIRCULATIONAHA.120.052278
Circulation Rodriguez F, Solomon N et. al.

Nov 17th, 2020 - Background: The COVID-19 pandemic has exposed longstanding racial/ethnic inequities in health risks and outcomes in the U.S.. We sought to identify racial/ethnic differences in presentation and outcomes for patients hospitalized with COVID-19. Methods: The American Heart Association COVID-19 Cardiovascular Disease Registry is a retrospective observational registry capturing consecutive patients...

In-line treatments and clinical initiatives to fight against COVID-19 outbreak.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567661
Respiratory Medicine; Agrawal M, Saraf S et. al.

Nov 17th, 2020 - In December 2019, when the whole world is waiting for Christmas and New Year, the physicians of Wuhan, China, are astounded by clusters of patients suffering from pneumonia from unknown causes. The pathogen isolated from the respiratory epithelium of the patients is similar to previously known coronaviruses with some distinct features. The disease was initially called nCoV-2019 or SARS-nCoV-2 a...

Compassionate use of remdesivir in children with COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7668659
European Journal of Pediatrics; Méndez-Echevarría A, Pérez-Martínez A et. al.

Nov 17th, 2020 - Children represent a minority of total COVID-19 cases, but studies have reported severe disease and death in pediatric patients. Remdesivir (RDV) has recently demonstrated promising results in adults with COVID-19, but few data have been reported to date in children.A nationwide multicenter observational study was conducted on children with confirmed SARS-CoV-2 receiving compassionate treatment...

Recent progress of antiviral therapy for coronavirus disease 2019.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7584884
European Journal of Pharmacology; Zhao M, Zhang J et. al.

Nov 16th, 2020 - The coronavirus disease 2019 (COVID-19) pandemic has become a global public health crisis, for which antiviral treatments are considered mainstream therapeutic approaches. With the development of this pandemic, the number of clinical studies on antiviral therapy, including remdesivir, chloroquine and hydroxychloroquine, lopinavir/ritonavir, ribavirin, arbidol, interferon, favipiravir, oseltamiv...

Drug therapy strategies for COVID-19 infection during pregnancy.
https://doi.org/10.5414/CP203817
International Journal of Clinical Pharmacology and Therapeutics; Wang H, Gao Y et. al.

Nov 16th, 2020 - Acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has spread rapidly in numerous countries and caused a massive number of deaths. Interferon-α (IFN-α), lopinavir/ritonavir, chloroquine phosphate, arbidol, ribavirin, remdesivir, and dexamethasone are the therapeutic drugs recommended for treating 2019-nCoV disease (COVID-19 disease). Due to the particularity of immune function, pregnant wome...

Why Not Try Melatonin, Zinc, Vit C? COVID-19 and Pascal's Wager
https://www.medscape.com/viewarticle/941041

Nov 16th, 2020 - Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. This transcript has been edited for clarity. Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine. Things are getting a bit bleak here in New Haven. Although my hospital has not reached the peak we saw in April, with 450 COVID-...

World's Top Intensive Care Body Advises Against Remdesivir for Sickest COVID Patients
https://www.staging.medscape.com/viewarticle/940935

Nov 15th, 2020 - BRUSSELS (Reuters) - Antiviral remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead. Remdesivir, also known as Veklury, and steroid dexamethasone are the only drugs authorised to treat COVID-19 patients across the w...

Randomized Controlled Trials for COVID-19: Evaluation of Optimal Randomization Methodol...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659806
International Journal of Antimicrobial Agents; Emani VR, Goswami S et. al.

Nov 15th, 2020 - During this emerging COVID-19 pandemic, initially there were no proven treatment options. With the release of randomized controlled trial results, we are beginning to see possible treatment options for COVID-19. The Recovery trials showed an Absolute Risk Reduction (ARR) in mortality by 2.8% with Dexamethasone, and the ACTT-1 trial showed that the treatment with Remdesivir reduced the Time to r...

SARS-CoV-2 triggering severe ARDS and secondary HLH in a 3-year-old child with Down syn...
https://doi.org/10.1093/jpids/piaa148
Journal of the Pediatric Infectious Diseases Society; Kim-Hellmuth S, Hermann M et. al.

Nov 14th, 2020 - Down syndrome (DS) predisposes to severe immunologic reaction secondary to infectious triggers. Here we report a paediatric DS patient with COVID-19 who developed a hyperinflammatory syndrome, severe ARDS and secondary HLH requiring PICU admission and treatment with steroids, IVIG and Remdesivir. Investigations into genetic susceptibilities for COVID-19 and SARS-CoV-2-associated complications w...

US Infectious Diseases Group Seeks More Data on Lilly COVID-19 Antibody Drug
https://www.medscape.com/viewarticle/940867

Nov 12th, 2020 - (Reuters) - The Infectious Diseases Society of America (IDSA) on Thursday said it is evaluating the data on which U.S. regulators approved emergency use of Eli Lilly and Co's COVID-19 antibody drug, and noted that more information is needed. The medical association, which represents more than 12,000 specialists, said its guidelines panel is evaluating available trial data and will issue its rec...

Herbal plants coordinate COVID-19 in multiple dimensions - An insight analysis for clin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646114
International Journal of Medical Sciences; Zhang Y, Li Y et. al.

Nov 11th, 2020 - The use of multipronged measures, including traditional Chinese medicine (TCM), has greatly increased in response to the COVID-19 pandemic, and we found the use of TCM and is positively correlated with the regional cure rate in China (R=0.77, P<10-5). We analyzed 185 commonly administered TCM recipes comprised of 210 herbs nationwide to reveal mechanistic insight. Eight out of the 10 most commo...

U.S. to Start Distributing Lilly COVID-19 Antibody This Week
https://www.medscape.com/viewarticle/940705

Nov 10th, 2020 - (Reuters) - The United States will this week begin distributing Eli Lilly and Co's COVID-19 antibody treatment to state health departments, Department of Health and Human Services (HHS) Secretary Alex Azar said on Tuesday. "Early treatment may help people avoid disease progression and avoid hospitalization," Janet Woodcock, director of the Food and Drug Administration's Center for Drug Evaluati...